Literature DB >> 28074307

Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience.

Takeshi Ninchoji1, Kandai Nozu2, Keita Nakanishi2, Tomoko Horinouchi2, Junya Fujimura2, Tomohiko Yamamura2, Shogo Minamikawa2, Shingo Ishimori2, Koichi Nakanishi3, Norishige Yoshikawa4, Ichiro Morioka2, Hiroshi Kaito2, Kazumoto Iijima2.   

Abstract

OBJECTIVES: To clarify the clinical characteristics and long-term outcomes of patients with diarrhea-associated hemolytic uremic syndrome (D + HUS) with a particular focus on time course.
METHODS: We retrospectively analyzed the medical records of 61 patients with D + HUS who were admitted to Kobe University Hospital between 1995 and 2015. The onset of D + HUS was defined as day 1 of diarrhea.
RESULTS: The age of onset was 4.1 (1.5-13.4) years, and the period between onset and diagnosis of D + HUS was 5 (3-18) days. The platelet count was lowest on day 7 (4-24), and the lactase dehydrogenase level was maximal on day 8 (4-25). Twenty-three patients required dialysis for 13 (2-37) days, starting at day 5-9. Seventeen patients showed central nervous system (CNS) symptoms at day 4-18. They were followed up for 3.7 (0-18.4) years. At the final follow-up, estimated glomerular filtration rate was 113.7 (57.9-159.9) ml/min/1.73 m2 with five patients having chronic kidney disease. Three patients developed CNS sequelae. The time to diagnosis was significantly shorter in the group of patients receiving dialysis than without dialysis (p = 0.018) and in the group with CNS complications than without (p = 0.013).
CONCLUSION: CNS complications were often apparent after blood examination results improved. Moreover, a shorter period between the onset of diarrhea and a diagnosis of D + HUS indicated a more severe clinical course or long-term sequelae, and it should be considered as a risk factor for poor prognosis.

Entities:  

Keywords:  Central nervous system complication; Dialysis; Hemolytic uremic syndrome; Kidney dysfunction

Mesh:

Year:  2017        PMID: 28074307     DOI: 10.1007/s10157-016-1376-3

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  19 in total

1.  Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak.

Authors:  S Dundas; J Murphy; R L Soutar; G A Jones; S J Hutchinson; W T Todd
Journal:  Lancet       Date:  1999-10-16       Impact factor: 79.321

2.  Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.

Authors:  Zbigniew M Szczepiorkowski; Jeffrey L Winters; Nicholas Bandarenko; Haewon C Kim; Michael L Linenberger; Marisa B Marques; Ravindra Sarode; Joseph Schwartz; Robert Weinstein; Beth H Shaz
Journal:  J Clin Apher       Date:  2010       Impact factor: 2.821

3.  Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study.

Authors:  Edin Colic; Hans Dieperink; Kjell Titlestad; Martin Tepel
Journal:  Lancet       Date:  2011-08-24       Impact factor: 79.321

4.  Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study.

Authors:  Osamu Uemura; Masataka Honda; Takeshi Matsuyama; Kenji Ishikura; Hiroshi Hataya; Nahoko Yata; Takuhito Nagai; Yohei Ikezumi; Naoya Fujita; Shuichi Ito; Kazumoto Iijima; Teruo Kitagawa
Journal:  Clin Exp Nephrol       Date:  2011-04-21       Impact factor: 2.801

5.  Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.

Authors:  Sylvie Nathanson; Thérésa Kwon; Monique Elmaleh; Marina Charbit; Emma Allain Launay; Jérôme Harambat; Muriel Brun; Bruno Ranchin; Flavio Bandin; Sylvie Cloarec; Guylhene Bourdat-Michel; Christine Piètrement; Gérard Champion; Tim Ulinski; Georges Deschênes
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

6.  Risk factors for developing severe clinical course in HUS patients: a national survey in Japan.

Authors:  Ichiro Kamioka; Kunihiko Yoshiya; Kenichi Satomura; Hiroshi Kaito; Teruo Fujita; Kazumoto Iijima; Koichi Nakanishi; Norishige Yoshikawa; Kandai Nozu; Masafumi Matsuo
Journal:  Pediatr Int       Date:  2008-08       Impact factor: 1.524

Review 7.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

8.  Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157.

Authors:  Takehisa Yamamoto; Kenichi Satomura; Shintaro Okada; Keiichi Ozono
Journal:  Pediatr Int       Date:  2009-04       Impact factor: 1.524

9.  Escherichia coli O-157-induced hemolytic uremic syndrome: Usefulness of SCWP score for the prediction of neurological complication.

Authors:  Takahide Teramoto; Toshiyuki Fukao; Kouichiro Hirayama; Tsutomu Asano; Yusuke Aoki; Naomi Kondo
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

Review 10.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

View more
  5 in total

1.  Unexpected diagnosis in a child with hemolytic uremic syndrome: Answers.

Authors:  Eimear Kirby; Shiraz Elbashier; Clodagh Sweeney; Eilish Twomey; Kathleen Gorman; Michael Riordan; Atif Awan
Journal:  Pediatr Nephrol       Date:  2021-03-17       Impact factor: 3.714

2.  Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.

Authors:  Ryan S McKee; David Schnadower; Phillip I Tarr; Jianling Xie; Yaron Finkelstein; Neil Desai; Roni D Lane; Kelly R Bergmann; Ron L Kaplan; Selena Hariharan; Andrea T Cruz; Daniel M Cohen; Andrew Dixon; Sriram Ramgopal; Annie Rominger; Elizabeth C Powell; Jennifer Kilgar; Kenneth A Michelson; Darcy Beer; Martin Bitzan; Christopher M Pruitt; Kenneth Yen; Garth D Meckler; Amy C Plint; Stuart Bradin; Thomas J Abramo; Serge Gouin; April J Kam; Abigail Schuh; Fran Balamuth; Tracy E Hunley; John T Kanegaye; Nicholas E Jones; Usha Avva; Robert Porter; Daniel M Fein; Jeffrey P Louie; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

3.  Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Battaglia; Ismael Toledo; Laura Beaudoin; Sandra Mariel Martin; Nicolás Ariel Grisolía; Ronald J Hogg
Journal:  Pediatr Nephrol       Date:  2022-10-13       Impact factor: 3.651

4.  Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.

Authors:  Laura F Alconcher; Paula A Coccia; Angela Del C Suarez; Marta L Monteverde; María Graciela Perez Y Gutiérrez; Paula M Carlopio; Mabel L Missoni; Alejandro Balestracci; Illiana Principi; Flavia B Ramírez; Patricia Estrella; Susana Micelli; Daniela C Leroy; Nahir E Quijada; Claudia Seminara; Marta I Giordano; Susana B Hidalgo Solís; Mariana Saurit; Alejandra Caminitti; Andrea Arias; Marta Rivas; Paula Risso; Miguel Liern
Journal:  Pediatr Nephrol       Date:  2018-06-30       Impact factor: 3.714

5.  Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood.

Authors:  Laura Vaterodt; Johannes Holle; Dieter Hüseman; Dominik Müller; Julia Thumfart
Journal:  Front Pediatr       Date:  2018-08-07       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.